Polygenic and familial contributions to antidepressant continuation, switching, discontinuation and augmentation in the All of Us and Pharmlines cohorts
Antidepressant switching partly indexes depression severity rather than drug-specific non-response alone, whereas augmentation captures cross-disorder psychiatric complexity, and familial aggregation was confined to sustained, switch-free continuation.
Abstract
Predicting antidepressant response remains a major challenge, and it is unclear whether reported polygenic associations reflect drug-specific non-response or a broader propensity for treatment modification. We analysed participants with at least one antidepressant monotherapy episode of [≥]28 days in the All of Us (AoU; n=98,357) and Pharmlines (Lifelines linked to IADB.nl; n=12,884) cohorts, comparing continuation with switching, discontinuation and augmentation (atypical antipsychotic or lithium) in relation to polygenic scores (PGS). Among individuals with recorded major depressive disorder, switching, but not discontinuation, was associated with anxiety, higher depression symptom count and stress-related measures in both cohorts. Depression PGS was associated with switching in AoU (OR=1.16 per SD, 95% CI 1.12-1.20), with a concordant nominally significant estimate in Pharmlines (OR=1.11, 1.01-1.22). In AoU, depression PGS increased progressively from continuation to switching to augmentation (per-step OR=1.18, 1.15-1.21), whereas schizophrenia and bipolar disorder PGS were selectively associated with augmentation. No PGS showed drug-class-specific associations with switching. Familial aggregation in Pharmlines was detectable for continuation, including SSRI and SNRI continuation, but not for switching or discontinuation. Antidepressant switching therefore partly indexes depression severity rather than drug-specific non-response alone, whereas augmentation captures cross-disorder psychiatric complexity, and familial aggregation was confined to sustained, switch-free continuation.
The results indicate that TRD does not represent a single, unified PGx-predicted 'poor pharmacological responder' phenotype but instead reflects a biologically heterogeneous collection of distinct PGx profiles, and actionable PGx phenotypes are neither enriched in TRD nor associated with greater TRD severity.
B. Roberts, A. Miljevic, Lauren A. Hennessy et al.· Pharmacogenetics & Genomics· 0 citations
Abstract Background Treatment-resistant depression (TRD), a subtype of major depressive disorder (MDD) defined by suboptimal response to antidepressant treatment, represents a significant unmet medical need. Vasopressin V1b receptor modulation has emerged as a potential mechanism relevant to stress-system dysregulation...
D. Gehrlach, L. Arvastson, C. zu Eulenburg et al.· International Journal of Neu...· 0 citations
Clinical features captured most of the predictable variance in episode duration, with the same predictors largely operating in opposite directions for short and long episodes, consistent with a continuum of chronicity.
L. Schindler, M. Singh, E. Sheridan et al.· medRxiv· 0 citations
Findings highlight an association between depression severity and self-reported stroke history, and both hypertension and diabetes were strong independent predictors of self-reported stroke, while higher income (PIR) was protective.
Himanshu Sharma, K. Reeta· Discover Public Health· 0 citations
GH001 was well tolerated and showed rapid, significant depressive symptom improvements in TRD, and data from the OLE indicate GH001 resulted in sustained remission over 6 months with infrequent treatments.
W. Cubała, K. Doolin, F. Ryan et al.· International Journal of Neu...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.